Clinical data and medium-term studies demonstrate that focal therapy—which targets only the specific cancerous zones within the prostate using modalities like high-intensity focused ultrasound, cryotherapy, or laser ablation—achieves high cancer control success rates while dramatically minimizing side effects. Studies indicate impressive metastasis-free survival rates reaching 95% to 98% and excellent cancer-specific survival metrics for appropriately selected intermediate-risk patients. Furthermore, functional success is exceptionally high, with vastly superior preservation of urinary continence and sexual potency compared to full-gland radical treatments.